MedTrace Logo

JAB-21822 Combined With Chemotherapy and Bevacizumab in Second-line KRAS G12C CRC

NCT06838338 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2026-01-08

No results posted yet for this study

Summary

KRAS is a common genetic mutation in tumors, and CRC is one of the tumors with a high KRAS mutation rate. The anti-tumor activity of KRAS G12C inhibitors combined with anti-EGFR anti-bodies have been proven in patients with advanced colorectal cancer, and one of them was approved for patients who have previously received standard treatment. However, Chinese patients still do not have access to these drugs. This study is to determine the efficacy and safety of KRAS G12C inhibitor JAB-21822 in combination with the second-line standard chemotherapy and bevacizumab in advanced colorectal cancer failed to standard therapy in Chinese population.

Conditions

Interventions

DRUG

JAB-21822

Tablet, oral, 800 mg/QD, until PD or intolerable toxicity

DRUG

standard second-line chemotherapy

The second line standard chemotherapy regimen recommended by clinical practice

DRUG

Bevacizumab

5mg/kg every two weeks (according to the assessment by investigator)

Sponsors & Collaborators

  • Jian Li

    lead OTHER

Principal Investigators

  • Jacobio Pharmaceuticals · Jacobio Pharmaceuticals

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-03-20
Primary Completion
2026-03-31
Completion
2026-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06838338 on ClinicalTrials.gov